Trial Profile
A study evaluating prognostic value of pre-treatment hematological markers for survival in patients with non small cell lung cancer treated with Nivolumab.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Jun 2017
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics; Therapeutic Use
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 26 Apr 2017 New trial record